{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:47:22Z","timestamp":1793227642745,"version":"4.5.0"},"reference-count":32,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Non\u2010alcoholic steatohepatitis (NASH) can adversely affect health\u2010related quality of life (HRQoL).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>This double\u2010blind, placebo\u2010controlled, phase 2 trial aimed to report the effects of the glucagon\u2010like peptide\u20101 receptor agonist, semaglutide, on HRQoL in patients with NASH as a secondary endpoint.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adults with biopsy\u2010proven NASH and stage 1\u20133 fibrosis were randomised (3:3:3:1:1:1) to once\u2010daily subcutaneous semaglutide 0.1, 0.2 or 0.4\u2009mg, or placebo, for 72\u2009weeks. Patients were invited to complete the Short Form\u201036 version 2.0 questionnaire at weeks 0, 28, 52 and 72.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Between January 2017 and September 2018, 320 patients were enrolled. At 72\u2009weeks, semaglutide was associated with significant improvements in physical component summary (PCS) score (estimated treatment difference [ETD] 4.26; 95% confidence interval [CI]: 1.96\u20136.55;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0003); bodily pain (ETD 5.07; 95% CI: 2.15\u20137.99;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0007); physical functioning (ETD 3.51; 95% CI: 1.16\u20135.86;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0034); role limitations due to physical health problems (ETD 2.80; 95% CI: 0.28\u20135.33;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0294); social functioning (ETD 3.16; 95% CI: 0.53\u20135.78;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0183) and vitality (ETD 4.47; 95% CI: 1.63\u20137.32;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0021). There was no significant difference in the mental component summary score (ETD 1.02; 95% CI: \u22121.59 to 3.62;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.4441). After 72\u2009weeks, improvements in PCS scores were significantly greater in patients (pooled semaglutide and placebo) with NASH resolution than without (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Treatment with semaglutide is associated with improvements in the physical components of HRQoL in patients with biopsy\u2010proven NASH and fibrosis compared with placebo.\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link>\n                      : NCT02970942.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/apt.17598","type":"journal-article","created":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:17:35Z","timestamp":1686961055000},"page":"395-403","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Improved health\u2010related quality of life with semaglutide in people with non\u2010alcoholic steatohepatitis: A randomised trial"],"prefix":"10.1111","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-8947","authenticated-orcid":false,"given":"Manuel","family":"Romero\u2010G\u00f3mez","sequence":"first","affiliation":[{"name":"UCM Digestive Diseases and CIBEREHD Virgen del Roc\u00edo University Hospital, Institute of Biomedicine of Seville (CSIC\/HUVR\/US), University of Seville  Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3425-1161","authenticated-orcid":false,"given":"Matthew J.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Department of Hepatology and Liver Transplantation Queen Elizabeth University Hospital Birmingham  Birmingham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4133-140X","authenticated-orcid":false,"given":"Jes\u00fas","family":"Funuyet\u2010Salas","sequence":"additional","affiliation":[{"name":"Department of Personality, Assessment and Psychological Treatment, Faculty of Psychology University of Seville  Seville Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal Kant","family":"Mangla","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen","family":"Ladelund","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne\u2010Sophie","family":"Sejling","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichhya","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Novo Nordisk A\/S  S\u00f8borg Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8682-5748","authenticated-orcid":false,"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[{"name":"Virginia Commonwealth University School of Medicine  Richmond Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029349"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2019.05.009"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22868"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.585425"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2020.100099"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28416"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.005"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028395"},{"key":"e_1_2_10_12_1","unstructured":"RAND Health Care.36\u2010Item Short Form Survey (SF\u201036) scoring instructions.https:\/\/www.rand.org\/health\u2010care\/surveys_tools\/mos\/36\u2010item\u2010short\u2010form\/scoring.html. 31 January 2022."},{"key":"e_1_2_10_13_1","volume-title":"User's manual for the SF\u201036v2 health survey","author":"Maruish ME","year":"2011"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40271-020-00485-w"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s41687-018-0052-7"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00803-X"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.039"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.2044"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.020"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(98)00108-5"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.02.024"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00213-0"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1037\/0003-066X.37.2.122"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(10)70676-9"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2015.08.021"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10102208"},{"key":"e_1_2_10_29_1","unstructured":"U.S. Food and Drug Administration.Patient\u2010reported outcome measures: use in medical product development to support labeling claims. Guidance for industry.2009.https:\/\/www.fda.gov\/regulatory\u2010information\/search\u2010fda\u2010guidance\u2010documents\/patient\u2010reported\u2010outcome\u2010measures\u2010use\u2010medical\u2010product\u2010development\u2010support\u2010labeling\u2010claims. Accessed 18 October 2021."},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-9-86"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199401000-00004"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.064"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.17598","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T22:42:36Z","timestamp":1692312156000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.17598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,16]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/apt.17598"],"URL":"https:\/\/doi.org\/10.1111\/apt.17598","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,16]]},"assertion":[{"value":"2023-01-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-19","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}